Torrent Pharmaceuticals to Commercialize Takeda's Novel Gastrointestinal Drug in India

Torrent Pharmaceuticals Limited has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in India. Vonoprazan is used for the treatment of acid related disorders, specifically Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie. The Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. The availability of P-CABs such as Kabvie will make new and effective treatments of GERD accessible for the Indian population. The agreement is expected to aid in reducing the disease burden of GERD and further strengthen Torrent's Gastrointestinal offerings, augmenting its position as a leading player within the Indian Pharmaceutical Market.